Welcome to the

Celestial Biolabs Limited

Celestial Biolabs Limited

Corporate Presentation
April 2013
 Product development Capabilities
Experienced Team of Scientist consisting Bioinformatics,
Molecular Biology, Medicinal Chemistry and Biotechnology.
Product development in the field of Branded Herbal Formulation,
Therapeutically peptide, Microbial Enzymes and Nutraceutical
Two way approach of finding new molecules having a short term
and medium term plan either through chemical synthesis or
biological route adopting applied research mechanism.
Reducing the time frame of molecule development by introducing
bioinformatics techniques
The continuous training and familiarization process with latest
drug discovery methodology
 Herbal and Nutraceutical Formulations

Identifying the disease of Interest.

Literature review
Finding out the active ingredients
Formulating with correct composition
Developing ,optimization and validating the process
Analytical testing
Toxicological testing (as applicable )
Efficacy testing and standardization
Filing for approval
Commercial production
Time frame 8-12 months
 Therapeutic Peptides Scenario

50+ Peptide-based 130+ Active Peptide

Therapeutics Approved Programs

Increasing levels of peptide R&D

over 30 years
Increasing number of peptide-based
NCEs
Increasing diversity of therapeutic
areas
Source: Reichert, J., Ph.D. (April 2010). Update on development trends for peptide therapeutics. Powerpoint presentation given at TIDES conference, Boston, MA
 Process Development of Peptide
Identifying the disease of Interest.
Literature review.
Study of the disease applicable pathway to establish
the target.
Finding the suitable molecular structure or peptide
sequence through insilico process.
Chemical route Biological Route
Developing and synthesizing Cloning and expression of the desired
peptide sequence .
the structure by adopting Process development and validation for
chemical route. fermentation and purification of the peptide.
Proceeding further for a Qualitative and quantitative estimation of the
validation through Preclinical peptide.
and clinical studies. Proceeding further for a validation through
invitro, Preclinical and clinical studies
 Targeted peptide Growth Strategy
Status of Novel Therapeutics
Peptides Focused On Vitiligo &
others at Celestial Biolabs.

Peptide for
Rational Design Anti-Wrinkling,
Wound healing
Lead Optimization
and Tanning
Preclinical Models Optimum time frame for commercial
Anti Vitiligo
Toxicology Peptide production(New Molecule)
Phase 1
Expected Year of commercialization
Phase 2 & Phase 3
combined
Vitiligo 2015
Commercialization
Tanning 2015
Anti wrinkling 2017
Wound healing 2017
 Development of Microbial Enzymes
Identifying the area of interest.
Literature review.
Identification and isolation of suitable organism/ host
Enzyme development through Mutatgensis / rDNA technology.
Strain development.
Development and validation of fermentation and purification
process.
Qualitative and quantitative estimation of the product to find
out yield, purity and activity per unit .
 Formulation of the enzyme.
Celestial Enzymes
Alpha amylase
Alkaline protease
Phytase
Serritaia peptidase
Cellulase
Lipase
 Development Team
 Dr.A.N.Singh Ph.D (Technology Management )
 Dr.Jeetinder Roy Gour Ph.D (Ayurveda & Pharmacology)
 Dr.D.C. Shastri Ph.D (Biochemistry )
 Dr.Balakrishna Ph.D (Biochemical Engineering )
 Dr.Ram Bhavani Ph.D (Organic Chemistry )
 Dr.Balram Bhavani Ph.D (Organic Chemistry )
 Dr.Chand Pasha Ph.D (Microbiology )
 Mr.P.V.Purnachandra Rao M.Sc (Biotechnology)
 Mr.Vijay Kumar M.Sc (Chemistry)
 Mr.D.Subba Reddy M.Sc (Bioinformatics)
 Mr. Harish Kumar M.Tech (Bioinformatics)
 Mr.K.Roopesh M.Sc (Bioinformatics)
 Mr. Chandan Kumar M.Sc (Bioinformatics)